Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma

• Verfasst von: Berger, Anne Katrin [VerfasserIn]
• Verfasst von: Weber, Tim [VerfasserIn]
• Verfasst von: Jäger, Dirk [VerfasserIn]
• Verfasst von: Springfeld, Christoph [VerfasserIn]
• Titel: Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma
• Verf.angabe: Anne K. Berger, Tim F. Weber, Dirk Jäger, Christoph Springfeld
• E-Jahr: 2013
• Jahr: November 20, 2013
• Umfang: 3 S.
• Fussnoten: Gesehen am 23.11.2020
• Titel Quelle: Enthalten in: Onkologie
• Ort Quelle: Basel : Karger, 1978
• Jahr Quelle: 2013
• Band/Heft Quelle: 36(2013), 12, Seite 763-765
• ISSN Quelle: 1423-0240
• DOI: doi:10.1159/000356811
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1740385705

Abstract

Background: Advanced pancreatic adenocarcinoma still remains associated with a desperate prognosis. Nevertheless, treatment options for patients with metastasized disease have improved considerably over the last few years. Recently, cytotoxic combination therapies such as the FOLFIRINOX regimen and combined nab-paclitaxel/gemcitabine have shown improved overall survival compared to gemcitabine alone. There is still no standard of care in second-line therapy for patients with disease progression. Case Report: We report the case of a 47-year-old patient who dramatically responded to second-line treatment with nab-paclitaxel and gemcitabine after primary progression to the FOLFIRINOX protocol. Conclusion: Second-line treatment after FOLFIRINOX is feasible for patients with good performance status. Our case report supports preclinical findings that suggest that pancreatic cancer is a heterogeneous disease. Further studies that characterize possible subgroups and identify predictive molecular markers to guide therapy are warranted.